Progesterone attenuates the effect of the 5-HT1A receptor agonist, 8-OH-DPAT,and of mild restraint on lordosis behavior

Ovariectomized, hormone-primed rats were used to test the hypothesis that progesterone treatment attenuated the effects of the 5-HT(1A) receptor agonist, (+/-)-8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT), on female rat lordosis behavior. Based upon prior evidence that prepriming with estradiol benzoate (EB) reduced the ability of 8-OH-DPAT to inhibit lordosis behavior, rats were preprimed with 10 microg EB 7 days before a second priming with 10 microg EB followed 48 h later with 500 microg progesterone or vehicle. Independent of the presence of progesterone, prepriming with EB attenuated the lordosis-inhibiting effects of systemic treatment with 8-OH-DPAT. However, progesterone also reduced the effects of 8-OH-DPAT and this effect was also seen in females primed only once with EB. In contrast, progesterone was relatively ineffective in attenuating the effects of bilateral infusion with 8-OH-DPAT into the ventromedial nucleus of the hypothalamus (VMN). The failure of progesterone to substantially reduce the effects of VMN infusion with 8-OH-DPAT contrasts with prior studies in which estrogen's protective action against the drug did include the VMN. Thus, while both estrogen and progesterone reduce the lordosis-inhibiting effect of 8-OH-DPAT, the mechanisms responsible for the effects of the two gonadal hormones may be different. Priming with progesterone also prevented the effects of 5 min of restraint. When rats were hormonally primed with EB and oil, rats showed a transient, but significant, decline in lordosis behavior 5 and 10 min after restraint. Rats primed with EB and progesterone were unaffected by the restraint. These results are discussed in terms of their implications for the role of progesterone in altering the 5-HT(1A) receptor modulation of lordosis behavior.     

WAY100635 and female rat lordosis behavior

Sexually receptive proestrous rats with bilateral cannulae in the ventromedial nucleus of the hypothalamus (VMN) were infused with 200 ng of (+/-)-8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT) or with 8-OH-DPAT plus varying concentrations (200 to 2000 ng) of the 5-HT1A receptor antagonist, N-[2[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]N-(2-pyridinyl)cyclohexanecarboxamide trihydrochloride (WAY100635). 8-OH-DPAT inhibited lordosis behavior within 15 min of the infusion and every dose of WAY100635 prevented the inhibition. When non-sexually receptive, ovariectomized rats, hormonally primed with 0.5 microg estradiol benzoate and 500 microg progesterone, were infused with WAY100635 (400 to 2000 ng), the 5-HT1A receptor antagonist did not facilitate lordosis responding. These findings support earlier findings that activation of 5-HT1A receptors in the mediobasal hypothalamus inhibits lordosis behavior. However, they further demonstrate that tonic activation of 5-HT1A receptors is not responsible for the absence of sexual receptivity in suboptimally hormonally primed ovariectomized rats.     

Effect of estrogen on the lordosis-inhibiting action of ketanserin and SB 206553

The effects of the 5-HT(2A/2C) receptor antagonist, ketanserin, and the 5-HT(2C) receptor antagonist, SB 206553, on lordosis behavior were investigated in ovariectomized rats hormonally primed with estradiol benzoate (EB) (0.5 or 25 microg) and progesterone (500 microg). Both ketanserin and SB 206553 inhibited lordosis behavior after infusion into the ventromedial nucleus of the hypothalamus (VMN), but ketanserin was slightly more effective than the 5-HT(2C) receptor antagonist. Either drug was more effective in rats primed with 0.5 microg EB than in rats hormonally primed with 25 microg EB. These findings support the suggestion that estrogen may enhance functioning of the 5-HT(2) receptor family and thereby protect against the 5-HT(2) receptor antagonists. These data are consistent with prior suggestions that estrogen modulates functioning of 5-HT(2) receptors within the VMN and that 5-HT(2) receptors play a facilitatory role in the modulation of female rat lordosis behavior.     

The PKC inhibitor, bisindolymaleimide, blocks DOI's attenuation of the effects of 8-OH-DPAT on female rat lordosis behavior

Ovariectomized rats with bilateral cannulae near the ventromedial nucleus of the hypothalamus were hormonally primed with 10 microg estradiol benzoate and 500 microg progesterone. Sexually receptive females were infused bilaterally with 200 ng of the 5-HT(1A) receptor agonist, 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT), or with a combination of 200 ng 8-OH-DPAT and 2000 ng of the 5-HT(2) receptor agonist, (+/-)-2,5-dimethoxy-4-iodophenyl-2-aminopropane HCl (DOI). 8-OH-DPAT inhibited lordosis behavior and DOI reduced this inhibition. However, if females were preinfused with the PKC inhibitor, bisindolymaleimide I hydrochloride (BIM), DOI's effect was eliminated. BIM's attenuation of the effects of DOI was time-dependent. When BIM was infused 90 min, but not 30 min, before the 5-HT receptor agonists, BIM eliminated DOI's protection against the lordosis-inhibiting effects of 8-OH-DPAT. A concentration of BIM as low as 10(-5) nmol in a 0.5 microl infusion volume was effective and there was little evidence of dose responsivity between 10(-5) and 10(-1) nmol of BIM. In contrast, prior infusion with vehicle or with 10(-7) nmol BIM had no impact on the female's response to the 5-HT receptor agonists. These findings allow the suggestion that DOI's ability to increase PKC may be responsible for attenuation of the effects of 8-OH-DPAT on lordosis behavior.     

Mild restraint reduces the time hormonally primed rats spend with sexually active males

The effect of 5 min of restraint on the time sexually-receptive females spend in the compartment of a sexually active male was examined. Ovariectomized females, hormonally primed with 10 microg estradiol benzoate and 500 microg progesterone (EP) or primed only with estradiol benzoate (EO) were used. After the restraint or home-cage experience, females were tested for 30 min in a chamber that allowed the female to escape to a small "burrow". Females, subjected to restraint, left the male's compartment faster and spent significantly less time in the male's compartment than did non-restrained females. This was true for both EP and EO females. When females were injected with the 5-HT(2B/2C)-receptor antagonist, SB 206553, 15 min before restraint, time spent in the male's compartment was even further reduced. However, additional studies indicated that it was the stress of the injection rather than the action of the drug that was responsible for the female's behavior. These findings are discussed in terms of their significance to the understanding of the female's reproductive response to stress and are compared to prior findings, where lordosis behavior was significantly reduced by restraint.     

Hormonal Activation of Female Sexual Behavior is Accompanied by Hypothalamic Norepinephrine Release

The present study employed the intracranial microdialysis technique to measure norepinephrine release in the ventrolateral dendritic fields of the ventromedial hypothalamus of freely-moving animals before and during ovarian steroid (estradiol and progesterone) activation of female sexual behavior (lordosis). One day after implantation of a dialysis probe, animals were injected with 3 μg of estradiol benzoate followed 44 h later by 200 μg of progesterone. Introduction of a male rat 4 h after progesterone treatment was correlated with dramatic increases in extracellular norepinephrine levels measured in dialysates of the ventrolateral ventromedial hypothalamus of female rats which displayed high levels of lordosis behavior. In contrast, female rats given the same steroid treatment but which did not show lordosis responses did not have elevated norepinephrine levels in their dialysates. Moreover, animals that received an estrogen antagonist concurrently with the estrogen treatment had neither an increase in ventromedial hypothalamic levels of norepinephrine during behavior testing nor did they display lordosis. These results indicate a close relationship among ovarian steroids, noradrenergic transmission in the ventromedial hypothalamus, and the expression of female sexual behavior.     

Cyclic GMP may potentiate lordosis behaviour by progesterone receptor activation

The purpose of this study was to test the hypothesis that cGMP acts as a progesterone substitute to facilitate lordosis in oestrogen-primed rats. Female Sprague-Dawley rats underwent stereotaxic surgery to place a 26-gauge guide cannula into the third ventricle. Bilateral ovariectomy was done at the same time as stereotaxic surgery. Five days later ovariectomized rats were primed with 2 microg estradiol benzoate 24 and 48 h prior to behaviour testing. Some animals were further injected with 200 microg progesterone 4 h before behaviour testing. A nitric oxide synthase inhibitor infused into the third ventricle before progesterone administration significantly reduced lordosis performance. 8-Bromo-cGMP, a cell permeable cGMP analogue, or saline vehicle was infused into the third ventricle of hormone-primed animals approximately 4 h prior to the first of 3-h behaviour tests. This cGMP analogue facilitated lordosis behaviour. We next used KT5823, a highly specific inhibitor of protein kinase G (PKG), to test the hypothesis that cGMP action is mediated by this kinase. In this experiment, KT5823 was infused 15 min before progesterone. KT5823 significantly decreased lordosis behaviour. RU486, a progesterone receptor antagonist, was used to assess whether the stimulatory effects of cGMP are mediated through the progesterone receptor. Oestrogen-primed animals were injected with 5 mg of RU486 or vehicle 60 min before infusion with 8-bromo-cGMP. RU486 significantly attenuated cGMP-facilitated lordosis behaviour. These data show that cGMP facilitates lordosis through activation of PKG and the progesterone receptor.     

The nitric oxide pathway participates in lordosis behavior induced by central administration of leptin

Intracerebroventricular (icv) administration of leptin facilitates lordosis behavior in ad libitum-fed, estrogen-primed rats. The cellular mechanism involved in this response is unknown. The present study tested the hypothesis that the nitric oxide-guanylyl cyclase, cGMP-dependent protein kinase (PKG) pathway is involved in the facilitation of lordosis behavior induced by the central administration of leptin. We tested the importance of the nitric oxide/cGMP pathway for lordosis stimulation by either icv infusion of a nitric oxide synthase inhibitor (L-NAME) or a nitric oxide-dependent, soluble guanylyl cyclase inhibitor (ODQ) 30 min before leptin administration (1 μg). This dose of leptin reliably induced lordosis behavior in ovariectomized estradiol benzoate treated rats. The lordosis induced by leptin at 1 and 2h after infusion was significantly reduced by the previous injection of either L-NAME or by ODQ. Intracerebroventricular infusion of the PKG inhibitor (KT5823) 30 min before leptin infusion, also significantly inhibited the lordosis behavior induced by leptin at 1 and 2h after hormone administration. These data support the hypothesis that the nitric oxide/cGMP/PKG pathway is involved in the facilitation of lordosis by leptin in estrogen-primed female rats.     

Oxytocin-induced facilitation of lordosis behaviour in rats is progesterone-dependent

Oxytocin was administered intracerebroventricularly to ovariectomized female rats and its effect on lordosis was examined. In Experiment 1a, oxytocin (0.17 mU in 4 microliters saline) failed to facilitate lordosis behaviour in animals primed acutely with 10 micrograms estradiol benzoate (EB) and 300 micrograms progesterone (P). In Experiment 1b, however, oxytocin significantly facilitated lordosis in animals primed acutely with 10 micrograms EB and 250 or 200 micrograms P. In Experiments 2a and 2b, oxytocin failed to facilitate lordosis in animals treated acutely with 10 micrograms EB, or chronically with 0.8 micrograms EB daily for eight days prior to testing. These results support the hypothesis that the facilitation of lordosis in ovariectomized rats by centrally-administered oxytocin is progesterone-dependent.     

Biochemical and Immunocytochemical Assessment of Neural Progestin Receptors Following Estradiol Treatments that Eliminate the Sex Difference in Progesterone-Facilitated Lordosis in Guinea-Pigs

A single injection of estradiol benzoate (10 μg), while highly effective in ovariectomized female guinea-pigs, does not prime castrated males to display progesterone-facilitated lordosis. In contrast, adult males and females exhibit the same, high degree of progesterone-facilitated lordosis when primed with two, 2.0 μg injections of free estradiol-17ß (pulse regimen). We compared neural progestin receptor induction after these different estradiol treatments by in vitro radioligand binding assays and immunocyto-chemistry. Binding assays confirmed previous observations of lower concentrations of cytosol progestin receptors in the mediobasal hypothalamus-preoptic area in estradiol benzoate-treated males than in females. No such sex difference was observed in animals that had been exposed to the behaviorally effective estradiol pulse regimen; rather, hypothalamic-preoptic area progestin receptor concentrations in these animals did not differ from the low levels observed in males treated with the behaviorally ineffective estradiol benzoate regimen. Immunocytochemical analysis revealed progestin receptor-immunoreactivity in fewer cells in the medial preoptic nucleus-anterior hypothalamic nucleus, periventricular preoptic area and arcuate nucleus of estradiol pulse- as compared to estradiol benzoate-treated males and females. Estradiol benzoate treatment induced progestin receptor-immunoreactivity in more cells in the medial preoptic area and ventrolateral hypothalamus than estradiol pulses in males, but not in females. Surprisingly, in these regions estradiol benzoate-treated males had significantly more progestin receptor-immunoreactive cells than females. These experiments yield two major findings: First, as has been shown in rats, the display of progesterone-facilitated lordosis is not inflexibly differentiated according to sex in guinea-pigs. Furthermore, reduced concentrations of estradiol-induced progestin receptors in the hypothalamus and preoptic area cannot account for the lack of progesterone-facilitated lordosis that is observed following priming with estradiol benzoate in males. Secondly, in the medial preoptic area and ventrolateral hypothalamus of female guinea-pigs, estradiol pulses are as effective as estradiol benzoate in inducing progestin receptors. These observations, taken together with the finding of equal behavioral efficacy of the two estradiol treatments, are consistent with the hypothesis that estradiol-induced progestin receptors in these regions of the brain are involved in progesterone-facilitated lordosis in female guinea-pigs.     

Influence of γ-aminobutyric acid on lordosis behavior and dopamine activity in estrogen primed spayed female rats

In the first experiment the role of γ-aminobutyric acid (GABA) in the display of lordosis behavior was examined in septal-lesioned and sham-operated ovariectomized rats. Following estradiol benzoate (EB) priming, septal-lesioned rats were tested for lordosis behavior before and after bilateral infusion of picrotoxin or saline directly into the substantia nigra (SN). Sham animals were given the same behavioral tests but received intranigral infusion of either hydrazinopropionic acid (HPA) or saline. Picrotoxin, which blocks GABA receptors, was effective in suppressing the hhgh levels of lordosis behavior seen in the EB-primed septal-lesioned female rat 30 min after infusion, but not at 120 min. Conversely, HPA, which elevates endogenous GABA levels, was effective in facilitating lordosis behavior in sham-operated rats treated with EB only. The lordosis quotient was moderately increased 30 min after HPA infusion, reached high levels at 120 min, and returned to low levels by 360 min post-infusion, demonstrating the reversibility of the drug effect. Saline infusions in lesioned and sham-operated controls were without effect. In the second experiment septal-lesioned and sham-operated rats were primed with EB and infused with the drugs as in the first experiment, but were sacrificed at the time the maximal behavioral effect has been observed in the first experiment. Tyrosine hydroxylase (TH) activity and dopamine (DA) and homovanillic acid (HVA) levels were measured. No effect on TH activity was found. However, sham-operated rats receiving HPA infusions had lower DA and receiving picrotoxin infusions had higher DA and HVA levels than those of lesioned saline-injected controls. Septal-lesioned saline-infused rats also showed decreased DA and HVA levels relative to sham-operated saline-infused animals. These results support the concept of a GABA inhibitory neuronal feedback system which modulates DA turnover and perhaps plays a critical role in the neural control of lordosis behavior.     

GABAergic drugs alter hypothalamic serotonin release and lordosis in estrogen-primed rats

The effects of muscimol, a GABA(A) agonist, and phaclofen, a GABA(B) antagonist, on serotonin (5HT) release in the mediobasal hypothalamus and lordosis behavior were studied in freely moving rats using in vivo microdialysis. Two days after implantation of bilateral guide cannulae directed towards the ventromedial nucleus of the hypothalamus (VMH), ovariectomized rats were primed with estradiol (E(2)). The rats were implanted with microdialysis probes 24 h later. Following a pretest for lordosis, perfusate 5HT was measured at 20-min intervals until the baseline was stable. The rats were treated with 10, 30 or 100 microM muscimol or 30 and 100 microM phaclofen in artificial CSF delivered via reverse dialysis for 40 min. Control animals were continuously perfused with artificial CSF. Behavior was tested 20, 60 and 180 min after introduction of the drug. Decreased hypothalamic 5HT (40-60% of baseline) and marked facilitation of lordosis were present 20 min after administration of either drug. The effects of 10 and 30 microM muscimol and 30 microM phaclofen on both 5HT and lordosis were reversed after 180 min. Reversal of the behavioral and neurochemical effects were not evident in either the 100 microM muscimol or 100 microM phaclofen groups at the time-points tested. Proceptive responses were observed in phaclofen-treated rats but not in rats treated with muscimol. Levels of hypothalamic 5HT and lordosis quotients in control rats did not significantly differ from initial values. These results suggest that GABAergic effects on lordosis may be mediated through an interaction with 5HT in the mediobasal hypothalamus.     

5-HT2C receptor involvement in female rat lordosis behavior

Adult, hormone-primed, ovariectomized rats (CDF-344) with bilateral implants within the ventromedial nucleus of the hypothalamus (VMN), were injected with 0.5 microgram estradiol benzoate followed 48 h later with 500 microgram progesterone. This priming produced rats with 2 different levels of sexual receptivity. Rats with a lordosis to mount ratio (L/M)>/=0.5 were used to examine the potential lordosis-inhibiting effects of the 5-HT2A receptor antagonist, R(+)-a-(2, 3-dimethoxyphenyl)-1-[2(4-fluoro-phenylethyl)]-4-piperidine-methanol (MDL 100,907), and the 5-HT2C receptor antagonist, 5-methyl-1-(3-pyridylcarbamoyl)-1,2,3,5-tetrahydropyrrolo[2, 3-f]indole (SB 206553). Rats with low sexual receptivity (L/M<0.5) were bilaterally infused with the 5-HT2A/2C receptor agonist, (+/-)-1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane HCl (DOI), or DOI plus either MDL 100,907 or SB 206553 to determine if either drug would attenuate the lordosis-facilitating effects of DOI. The 5-HT2C receptor antagonist, but not the 5-HT2A receptor antagonist, effectively inhibited lordosis behavior. Similarly, SB 206553 was more effective than MDL 100,907 in reducing the DOI-induced increase in lordosis responding. However, both drugs limited the duration of lordosis responding initiated by DOI. These results are consistent with prior suggestions that 5-HT2A/2C receptors within the VMN are involved in the modulation of lordosis behavior and lead to the suggestion that 5-HT2C, rather than 5-HT2A, receptors are primarily responsible for the effects of 5-HT2 receptor-active drugs on lordosis behavior.     

GnRH mediates estrous behavior induced by ring A reduced progestins and vaginocervical stimulation

The present study was designed to assess the participation of gonadotropin-releasing hormone (GnRH) in the display of estrous behavior induced by application of vaginal-cervical stimulation (VCS) and by the intracerebroventricular (icv) administration of progesterone and its ring A-reduced metabolites to ovariectomized (ovx), estradiol benzoate (E2B) primed rats. Icv injection of Antide, a GnRH-1 receptor antagonist, significantly depressed lordosis behavior in ovx, E2B-primed rats treated with icv GnRH. Application of VCS to ovx, E2B-primed rats facilitated both lordosis and proceptivity. These behavioral responses were significantly depressed by the icv administration of Antide. Similarly, icv Antide blocked the stimulatory effect on both lordosis and proceptive behaviors elicited by progesterone and its ring A-reduced metabolites: 5alpha-pregnandione (5alpha-DHP), 5alpha-pregnan-3alpha-ol-20-one (5alpha,3alpha-Pgl) and 5beta-pregnan-3beta-hydroxy-20-one (5beta,3beta-Pgl) in ovx, E2B-primed rats. By contrast, icv injection of Antide failed to interfere with the facilitatory effect of the synthetic progestin megestrol acetate on lordosis and proceptive behaviors. This progestin is not reduced in ring A. The results suggest that GnRH release is an important process in the chain of events leading to the display of estrous behavior in response to progesterone, its ring A-reduced metabolites, and VCS in female rats.     

Lordosis-inhibiting effect of progesterone in male and female rats with septal lesions

The inhibitory role of progesterone (P) in regulating lordosis was investigated in male and female rats with septal lesions (SL). Male rats with SL showed lordosis quotients (LQ) as high as female rats with SL and female control rats without brain surgery after injection of 50 microg/kg estradiol benzoate (EB) followed by 0.5 mg P 44 h later. Even when primed with 5 mg P 1 h prior to the 50 microg EB-injection, the mean LQs were still high in all groups. When the dose of EB was decreased to 5 microg/kg, all rats showed high-score LQs. In contrast, all animals in both male and female in which 5 mg P was injected 1 h before 5 microg EB, showed low LQs. These results suggest that P is effective in suppressing lordosis enhanced by estrogen in either male rats or females. Furthermore, the high dose of estrogen overcomes the inhibitory action of P on lordosis in both sexes.     

Estrous cycle modulation of extracellular serotonin in mediobasal hypothalamus: role of the serotonin transporter and terminal autoreceptors.

In vivo microdialysis was used to examine extracellular serotonin (5-HT) in the mediobasal hypothalamus (MBH) of male and female Fischer (CDF-344) rats. Females from the stages of diestrus, proestrus, and estrus were used. Additionally, ovariectomized rats, primed subcutaneously (s.c.) with estradiol benzoate or estradiol benzoate plus progesterone were examined. Extracellular 5-HT in the MBH varied with stage of the estrous cycle and with the light/dark cycle. Proestrous females had the highest microdialysate concentrations of 5-HT during the light portion of the light/dark cycle and lowest concentrations during the dark portion of the cycle. Diestrous females had the highest levels during the dark portion of the cycle, while males and estrous females showed little change between light and dark portions of the cycle. In ovariectomized rats, there was no effect of 2.5 microg or 25 microg estradiol benzoate (s.c.) on extracellular 5-HT; but the addition of 500 microg progesterone, 48 h after estrogen priming, reduced microdialysate 5-HT near the threshold for detection. In intact females and in males, reverse perfusion with 3 microM fluoxetine, a selective serotonin reuptake inhibitor (SSRI), or 2 microM methiothepin, a 5-HT receptor antagonist, increased microdialysate concentrations of 5-HT. Estrous females and males showed nearly a 4-fold increase in microdialysate 5-HT in response to fluoxetine while smaller responses were seen in diestrous and proestrous rats. In contrast, proestrous rats showed the largest response to methiothepin. Estrous females showed a delayed response to methiothepin, but there was no methiothepin-induced increase in extracellular 5-HT in males. These findings are discussed in reference to the suggestion that extracellular 5-HT in the MBH is regulated in a manner that is gender and estrous cycle dependent. The 5-HT terminal autoreceptor may exert a greater role in proestrous females; the serotonin transporter appears to play a more active role in the regulation of extracellular 5-HT in estrous females and in males.     

Hypothalamic progesterone implants and facilitation of lordosis behavior in estrogen-primed ovariectomized guinea pigs

Adult ovariectomized Hartley guinea pigs were bilaterally implanted in the basal hypothalamus or anterior hypothalamic-preoptic area with stainless steel cannulae with removable inserts. In experiment 1, animals received inserts containing crystalline progesterone, 17α-hydroxyprogesterone or cholesterol 36 h after subcutaneous injection of 3.3 μg estradiol benzoate. Regardless of cannula content, about 43% of animals with implants aimed at the basal hypothalamus displayed heat. Lesions or irritation associated with implants in this region may have increased behavioral responsiveness to estrogen. However, control implanted animals (17α-hydroxyprogesterone and cholesterol) tended to have shorter heat durations and more scattered facilitatory implant sites than progesterone implanted animals, suggesting that progesterone might be acting in basal hypothalamus to facilitate lordosis. Progesterone placed in basal anterior hypothalamic-preoptic area did not facilitate lordosis. Progesterone in basal hypothalamus or basal anterior hypothalamic-preoptic area did not produce inhibitory effects on behavior.In experiment 2, a revised procedure was used to control for sexual behavior resulting from estrogen treatment alone. The control procedures revealed that most of the animals with cannulae in the ventromedial-arcuate area displayed lordosis after estradiol benzoate alone. When animals not displaying estrus in response to estradiol benzoate alone were utilized for further implantation, it was clear that progesterone placed in the ventromedial-arcuate-premammillary area facilitated the expression of short latency, long duration heat. However, animals with cannulae in the basal hypothalamus, regardless of cannula content, had short maximum lordoses. No inhibitory effects of progesterone implants (in ventromedial-arcuate-premammillary area) on lordosis were observed. These results suggest that brain sites selectively responsive to the facilitatory actions of progesterone exist in the ventromedial-arcuate-premammillary region and that the whole basal hypothalamus participates in the normal, full expression of guinea pig behavioral estrus.     

The role of insulin-like growth factor-I and growth factor-associated signal transduction pathways in estradiol and progesterone facilitation of female reproductive behaviors

We are examining the role of insulin-like growth factor-I (IGF-I) and downstream signal transduction pathways associated with growth factors (e.g., mitogen-activated protein kinase, MAPK) in estradiol and progesterone facilitation of female reproductive behavior in rats. Brain IGF-I receptor activity is required for the long-term, priming actions of estradiol on the female reproductive axis. Infusions of an IGF-I receptor antagonist during estradiol priming blocks induction of hypothalamic alpha(1B)-adrenergic receptors and luteinizing hormone surges, and attenuates lordosis behavior. Infusion of MAPK and phosphatidylinositol-3-kinase inhibitors inhibitors during estradiol priming completely blocks hormone-facilitated lordosis. Because progestin receptors (PRs) can be phosphorylated and activated by MAPKs, growth factor signaling pathways may also participate in progesterone facilitation of reproductive behaviors. Infusion of a MAPK inhibitor in estradiol-primed rats blocks progestin facilitation and sequential inhibition of lordosis and proceptive behaviors. Interference with MAPK signaling also inhibits behavioral responses to cGMP and a delta-opioid agonist, both of which can activate MAPK in some cells. Thus MAPK is involved in the facilitation of lordosis and proceptive behaviors, perhaps by phosphorylation of hypothalamic PRs.     

Activation of protein kinase C in the hypothalamic ventromedial nucleus or the midbrain central gray facilitates lordosis

Many neurotransmitters and neuropeptides can act through the hypothalamic ventromedial nucleus (VMN) or midbrain central gray (MCG) to facilitate lordosis. Since these lordosis-facilitating agents can also stimulate the phosphoinositide (PI) second-messenger pathway, it was hypothesized that direct activation of this pathway can also potentiate the behavior. To evaluate this possibility, a phorbol ester, TPA (12-O-tetradecanoyl phorbol 13-acetate), was used to activate a key enzyme, protein kinase C (PKC), of the PI pathway in ovariectomized (OVX) rats either primed or not primed with estrogen. These female rats were paired with males for mating tests before and after an intracerebral infusion of TPA, and both the lordosis quotient (LQ) and the lordosis strength (LS) were measured. Bilateral infusion of TPA (5 μg/0.5 μl or 0.2 μg/0.2 μl, but not 0.1 μg/0.2 μl/side) into the VMN or MCG of estrogen-primed subjects facilitated both LQ and LS in 30 min, peaked at 60–90 min, and the facilitation lasted for more than 180 min. This facilitatory effect of TPA was: (1) not observed in OVX rats not primed with estrogen; (2) not observed if the infused TPA did not reach both sides of the VMN or MCG; (3) not mimicked by 4-phorbol 12,13-didecanoate, which does not activate PKC; (4) blocked by PKC inhibitors (H7 10 mM or staurosporine 1 μM, 0.2 μl/ side), which by themeselves did not facilitate lordosis; and (5) was not affected by pretreatment of the progestin antagonist RU486. These observations indicate that TPA facilitates lordosis in a dose-dependent fashion by activating, and not by depleting, PKC in the VMN or MCG, and that the TPA effect requires estrogen priming but not the activation of progestin receptors. Thus, the PI pathway or the activation of PKC may be a common mediator for lordosis facilitation in these two brain regions; and the requirement of estrogen priming further raises the possibility that this second-messenger system or its substrates in the VMN and MCG are modulated by estrogen.     

Failure of chlordecone (Kepone) to induce behavioral estrus in adult ovariectomized rats

The effect of chlordecone on behavioral estrus was examined in adult ovariectomized female rats. Chlordecone has been reported to resemble estrogen in altering pituitary secretions, in producing vaginal cornification, in increasing uterine weight and in competing for binding to the estrogen receptor. In the present study, 10, 25, 50 or 75 mg/kg chlordecone was substituted for estrogen in the estrogen-progesterone priming sequence used to facilitate sexual behavior of ovariectomized female rats. Sexual receptivity was measured by the number of lordosis responses exhibited by the female when mounted by a sexually active male. Chlordecone failed to substitute for estradiol in producing lordosis behavior. When female rats were given chlordecone in addition to estrogen plus progesterone, chlordecone reduced the lordosis behavior usually seen in these steroid primed animals. In further studies, chlordecone's effect on the CNS progesterone receptor was examined. Unlike estradiol, chlordecone did not induce progesterone receptors. Furthermore, chlordecone attenuated the increase in progesterone receptors seen after estradiol treatment. These findings suggest that chlordecone fails to mimic, and may actually interfere with, estrogen's facilitative effects on neurally mediated reproductive events.